“黑真菌”-新型冠状病毒期间令人担忧的感染-综述

Q4 Medicine
Raneet Das, Jayita Roy, Sumel Ashique
{"title":"“黑真菌”-新型冠状病毒期间令人担忧的感染-综述","authors":"Raneet Das, Jayita Roy, Sumel Ashique","doi":"10.2174/2211352520666220329160041","DOIUrl":null,"url":null,"abstract":"\n\nMucormycosis is a most emerging angioinvasive fungal infection of filamentous fungi of zygomycetes class, which on neglecting, causes severe disseminated infection along with significant chances of morbidity and mortality. The diagnosis and treatment remain a bit of a challenging case for the doctors. It has been seen that people who have been suffering from different diseases, such as hematological malignancies, uncontrolled diabetes, or gone through different surgeries, such as hematopoietic stem cell transplant, solid transplantation, are the ones affected by the most. On the other hand, people who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) typically show the symptoms of mucormycosis after (1-2) weeks of successful recovery. Standard treatment of mucormycosis is traditionally considered an amphotericin B intravenous (IV) drug as initial therapy, although posaconazole and isavuconazole are also used. The core objective of the review is to typically focus on the area of the sudden cause of effecting mucormycosis on the patients who have already recovered from SARS-CoV-2.\n","PeriodicalId":7951,"journal":{"name":"Anti-Infective Agents","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"‘Black Fungus’- An alarming infection during novel coronavirus- A Review\",\"authors\":\"Raneet Das, Jayita Roy, Sumel Ashique\",\"doi\":\"10.2174/2211352520666220329160041\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nMucormycosis is a most emerging angioinvasive fungal infection of filamentous fungi of zygomycetes class, which on neglecting, causes severe disseminated infection along with significant chances of morbidity and mortality. The diagnosis and treatment remain a bit of a challenging case for the doctors. It has been seen that people who have been suffering from different diseases, such as hematological malignancies, uncontrolled diabetes, or gone through different surgeries, such as hematopoietic stem cell transplant, solid transplantation, are the ones affected by the most. On the other hand, people who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) typically show the symptoms of mucormycosis after (1-2) weeks of successful recovery. Standard treatment of mucormycosis is traditionally considered an amphotericin B intravenous (IV) drug as initial therapy, although posaconazole and isavuconazole are also used. The core objective of the review is to typically focus on the area of the sudden cause of effecting mucormycosis on the patients who have already recovered from SARS-CoV-2.\\n\",\"PeriodicalId\":7951,\"journal\":{\"name\":\"Anti-Infective Agents\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anti-Infective Agents\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/2211352520666220329160041\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-Infective Agents","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2211352520666220329160041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

毛霉病是接合菌纲丝状真菌的一种新兴的血管侵袭性真菌感染,若忽视,可引起严重的播散性感染,发病率和死亡率高。对医生来说,诊断和治疗仍然是一个有点挑战性的案例。据调查,患有恶性血液病、糖尿病等不同疾病或接受过造血干细胞移植、实体移植等不同手术的人受到的影响最大。另一方面,从严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)中康复的人通常在成功康复(1-2)周后出现毛霉病症状。毛霉病的标准治疗传统上被认为是两性霉素B静脉注射(IV)药物作为初始治疗,尽管泊沙康唑和异戊康唑也被使用。审查的核心目标通常是关注对已经从SARS-CoV-2中恢复的患者产生毛霉菌病的突然原因的区域。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
‘Black Fungus’- An alarming infection during novel coronavirus- A Review
Mucormycosis is a most emerging angioinvasive fungal infection of filamentous fungi of zygomycetes class, which on neglecting, causes severe disseminated infection along with significant chances of morbidity and mortality. The diagnosis and treatment remain a bit of a challenging case for the doctors. It has been seen that people who have been suffering from different diseases, such as hematological malignancies, uncontrolled diabetes, or gone through different surgeries, such as hematopoietic stem cell transplant, solid transplantation, are the ones affected by the most. On the other hand, people who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) typically show the symptoms of mucormycosis after (1-2) weeks of successful recovery. Standard treatment of mucormycosis is traditionally considered an amphotericin B intravenous (IV) drug as initial therapy, although posaconazole and isavuconazole are also used. The core objective of the review is to typically focus on the area of the sudden cause of effecting mucormycosis on the patients who have already recovered from SARS-CoV-2.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Anti-Infective Agents
Anti-Infective Agents Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
1.50
自引率
0.00%
发文量
47
期刊介绍: Anti-Infective Agents publishes original research articles, full-length/mini reviews, drug clinical trial studies and guest edited issues on all the latest and outstanding developments on the medicinal chemistry, biology, pharmacology and use of anti-infective and anti-parasitic agents. The scope of the journal covers all pre-clinical and clinical research on antimicrobials, antibacterials, antiviral, antifungal, and antiparasitic agents. Anti-Infective Agents is an essential journal for all infectious disease researchers in industry, academia and the health services.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信